Leggett action continues

By Dylan Bushell-Embling
Tuesday, 16 September, 2008

Legal action against former Agenix CEO Neil Leggett is set to re-commence before the Supreme Court of Victoria on September 26.

Agenix [ASX: AGX] is taking action against Leggett, a former CEO, CFO and company secretary, alleging financial irregularities involving $3.865 million.

Agenix alleges that improper transactions occurred between it and a trustee company of Leggett’s family trust.

A stay of proceedings was ordered on September 12 as the trustee company has been placed into a creditor’s voluntary liquidation.

Leggett was with the company between 2003 and May 2008.

Agenix has been hit with further problems recently, with an intended acquisition in China stalling and two directors and the company chairman resigning in August.

It recently received a patent for its ThromboView technology in New Zealand. ThromboView is a humanised D-dimer antibody diagnostic with a range of imaging and therapeutic applications.

It is currently in Phase II trials in Canada and the US for the detection of pulmonary embolism.

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd